GYNISUS

Company Overview

Snapshot

Founded in January 2017 by Hila Friedmann, Zoya Gordon, and Israel Meizner, GYNISUS operates with 11–50 employees. The company has raised $50,000 across three funding rounds. In March 2023, Plug and Play led a Seed funding round.

Business overview

GYNISUS is a Health Tech & Life Sciences company that leverages artificial intelligence to enhance diagnosis and treatment within the healthcare sector. Its core offering, the SPAI platform, delivers intelligent insights and predictions. The company's Infectious Disease Intelligence Platform, powered by SPAI, supports hospitals, home nursing facilities, and senior living centers by identifying individuals likely to be infected with viruses like COVID-19 and their contacts, aiming to slow disease spread. GYNISUS primarily serves hospitals and physicians, enabling them to focus on high-risk patients and improve forecasting for resource utilization and cost management. The company operates in the Digital Health and Medical Technologies sector, with a focus on Digital Medical Diagnostics and Medical Decision Support, serving geomarkets including the United States, Israel, Europe, India, and Brazil.

Company Intelligence Q&A

What is the primary focus of GYNISUS's technology?

GYNISUS utilizes artificial intelligence through its SPAI platform to provide intelligent insights and predictions for the healthcare space, aiming to improve diagnosis and treatment.

What is the status of GYNISUS?

GYNISUS is currently Non Active and ceased to operate in August 2024.

When was GYNISUS founded and by whom?

GYNISUS was founded in January 2017 by co-founders Hila Friedmann, Zoya Gordon, and Israel Meizner.

What was a key funding event for GYNISUS?

The round was led by Plug and Play.

Which markets does GYNISUS serve?

GYNISUS targets geomarkets including the United States, Israel, Europe, India, and Brazil.